Dickson BD - Search Results

1

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Hong CR, Liew LP, Wong WW, Dickson BD, Cheng G, Shome A, Airey R, Jaiswal J, Lipert B, Jamieson SMF, Wilson WR, Hay MP. Hong CR, et al. Among authors: dickson bd. J Med Chem. 2024 Jul 25;67(14):12366-12385. doi: 10.1021/acs.jmedchem.4c01120. Epub 2024 Jul 15. J Med Chem. 2024. PMID: 39007759 Free PMC article.

2

Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.

Wong WW, O'Brien-Gortner SF, Anderson RF, Wilson WR, Hay MP, Dickson BD. Wong WW, et al. Among authors: dickson bd. RSC Med Chem. 2023 Jun 8;14(7):1309-1330. doi: 10.1039/d3md00117b. eCollection 2023 Jul 20. RSC Med Chem. 2023. PMID: 37484567 Free PMC article.

3

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors.

Dickson BD, Wong WW, Wilson WR, Hay MP. Dickson BD, et al. Molecules. 2019 Apr 19;24(8):1559. doi: 10.3390/molecules24081559. Molecules. 2019. PMID: 31010230 Free PMC article.

4

Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.

Lee TW, Wong WW, Dickson BD, Lipert B, Cheng GJ, Hunter FW, Hay MP, Wilson WR. Lee TW, et al. Among authors: dickson bd. Int J Radiat Biol. 2019 Dec;95(12):1597-1612. doi: 10.1080/09553002.2019.1664787. Epub 2019 Sep 17. Int J Radiat Biol. 2019. PMID: 31490091

5

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.

Wong WW, Jackson RK, Liew LP, Dickson BD, Cheng GJ, Lipert B, Gu Y, Hunter FW, Wilson WR, Hay MP. Wong WW, et al. Among authors: dickson bd. Biochem Pharmacol. 2019 Nov;169:113641. doi: 10.1016/j.bcp.2019.113641. Epub 2019 Sep 18. Biochem Pharmacol. 2019. PMID: 31541630

6

Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.

Hong CR, Buckley CD, Wong WW, Anekal PV, Dickson BD, Bogle G, Hicks KO, Hay MP, Wilson WR. Hong CR, et al. Among authors: dickson bd. Radiother Oncol. 2022 Jan;166:162-170. doi: 10.1016/j.radonc.2021.11.027. Epub 2021 Nov 30. Radiother Oncol. 2022. PMID: 34861268

7

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR. Hong CR, et al. Among authors: dickson bd. Biochem Pharmacol. 2018 Oct;156:265-280. doi: 10.1016/j.bcp.2018.08.027. Epub 2018 Aug 19. Biochem Pharmacol. 2018. PMID: 30134191

8

Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer.

Lee TW, Lai A, Harms JK, Singleton DC, Dickson BD, Macann AMJ, Hay MP, Jamieson SMF. Lee TW, et al. Among authors: dickson bd. Cancers (Basel). 2020 Dec 12;12(12):3743. doi: 10.3390/cancers12123743. Cancers (Basel). 2020. PMID: 33322840 Free PMC article. Review.

9

Determining the optimal dosage regimen for H2-receptor antagonist therapy--a dose validation approach.

Young MD, Frank WO, Dickson BD, Peace KP, Braverman A, Mounce W. Young MD, et al. Among authors: dickson bd. Aliment Pharmacol Ther. 1989 Feb;3(1):47-57. doi: 10.1111/j.1365-2036.1989.tb00190.x. Aliment Pharmacol Ther. 1989. PMID: 2577482 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters